The Korea Communications Standards Commission (hereinafter referred to as KCSC) announced on the 11th that it held a Communications Review Subcommittee meeting and decided to request corrective measures such as access blocking for 13 cases of illegal advertisements and sales information related to the obesity treatment drug 'Wegovy'.
On the 16th, the day the global pharmaceutical company Novo Nordisk's obesity treatment drug "Wegovy" was launched in South Korea, a notice saying "Belly Fat Medicine In Stock" was posted at a pharmacy in Jongno-gu, Seoul. Photo by Jinhyung Kang aymsdream@
Wegovy is an obesity treatment drug officially launched domestically on the 15th of last month and is a prescription drug that requires a doctor's prescription. Therefore, reviews and advertising information sharing prices and other details targeting the general public online, as well as information selling or brokering sales or advertising, violate the Pharmaceutical Affairs Act.
The KCSC stated, "As social interest and demand for the recently officially launched domestic obesity treatment drug 'Wegovy' have increased, illegal online sales have also been rampant," adding, "We decided to promptly block related information to respond in a timely manner."
The KCSC plans to actively cooperate with related organizations such as the Ministry of Food and Drug Safety to actively respond to illegal food and drug advertisements and sales information.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
